Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced that its President and CEO, Dr. David J. Mazzo, will deliver a company presentation at the Sequire Investor Summit on January 24, 2024. The summit will focus on the development of innovative therapies for advanced solid tumors and serious diseases.
01/18/2024 - 08:30 AM
BASKING RIDGE, NJ, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will deliver a company presentation at the upcoming Sequire Investor Summit being held January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
Dr. Mazzo’s presentation will be held on Wednesday, January 24, 2024, at 10:00am Atlantic Standard Time. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/ .
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1 , is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com .
About SRAX
SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire srax.com mysequire.com
Contact:
Investors and Media:
When and where will Dr. David J. Mazzo deliver the company presentation?
Dr. David J. Mazzo will deliver the company presentation at the Sequire Investor Summit on January 24, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
What is the focus of the upcoming Sequire Investor Summit?
The summit will focus on the development of innovative therapies for advanced solid tumors and other serious diseases.
What is the ticker symbol for Lisata Therapeutics, Inc.?
The ticker symbol for Lisata Therapeutics, Inc. is LSTA.
Who is the President and CEO of Lisata Therapeutics, Inc.?
Dr. David J. Mazzo is the President and CEO of Lisata Therapeutics, Inc.
LSTA Rankings
#4732 Ranked by Stock Gains
LSTA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Country
US
City
Basking Ridge
About LSTA
caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.
